Effectiveness of Intensive Insulin Therapy by Multiple Daily Injections and Continuous Subcutaneous Infusion: A Comparison Study in Type 2 Diabetes with Conventional Insulin Regimen Failure

Berthe, E.; Lireux, B.; Coffin, C.; Goulet-Salmon, B.; Houlbert, D; Boutreux, S.; Fradin, Sabine; Reznik, Yves

doi:10.1055/s-2007-970423

Cited by 92 publications

(121 citation statements)

References 9 publications

(12 reference statements)

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…16,17 In previously published findings of the present16-week study, CSII in patients with type 2 diabetes was found to be preferred to patients' previous treatment regimens 18 and to significantly improve both HbA1c and self-monitored 7-point glucose profiles. 19,20 The aim of the present post hoc analysis of samples from the same study was to test the hypothesis that these benefits in glycemic control were reflected in depression of a marker of oxidative stress.…”

mentioning

confidence: 55%

Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes

Megson

Treweeke

Shaw

et al. 2015

J Diabetes Sci Technol

View full text Add to dashboard Cite

The incidence of type 2 diabetes is increasing rapidly and, with it, the requirement for insulin therapy in advanced disease. 1 Poor glycemic control, as measured by glycated haemoglobin (HbA1c), has long been linked to mortality associated with diabetes 2 and improvement in control is associated with reduced complications.3 However, intensive therapy to achieve near-normal HbA1c levels in patients with type 2 diabetes has not been shown to reduce cardiovascular events 3,4 and is associated with a rise in all-cause mortality. 4 The link between diabetes and vascular disease is complex, but oxidative stress, mediated by increased prevalence of harmful reactive oxygen species (ROS), is associated with type 2 diabetes and has been implicated both in its progression via β-cell dysfunction, and with macro-and microvascular diabetes complications. 5-7 There is a close relationship between plasma-borne markers of oxidative stress (eg, oxidized low density lipoprotein [ox-LDL]) and risk of coronary artery disease and stroke. 8,9 The origins of 570359D STXXX10.

show abstract

mentioning

confidence: 55%

Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes

Megson

Treweeke

Shaw

et al. 2015

J Diabetes Sci Technol

View full text Add to dashboard Cite

show abstract

“…In studies with DM2, the use of CSII was associated with better metabolic control, and the rate of hypoglycemia was similar to the use of three daily injections of lispro and NPH (22). The improvement in A1c was also observed with greater intensity in type 2 diabetics with poor control and persisted during the six years of use CSII (23).…”

Section: Discussionmentioning

confidence: 82%

Evaluation of diabetic patients after three month use of continuous subcutaneous insulin infusion, dispensed by a protocolled form at outpatient reference clinic of Taguatinga Regional Hospital

Miranda¹,

Pedrosa²,

Falleiros³

et al. 2015

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: To evaluate the data of continuous subcutaneous insulin infusion protocol (CSII) for diabetics waived by the Health State Secretariat of Distrito Federal (HSSDF) and therapeutic responses three months after the transfer of multiple daily injections regimen for CSII. Subjects and methods: Eighty patients (49 female) took part in this experimental study, mean age and disease duration were 27.9 years and 13 years, respectively; 96% patients had type 1 diabetes mellitus. Results: The entire sample (ECO) and 3 subgroups (group 1 -A1c decrease, group 2 -A1c stable, and group 3 -A1c increase), stratified according to a ≥ 0.5% change in A1c, were analyzed. Group 1 involved 64% of the patients. The ECO showed a significant A1c decrease: MDI 8.1 ± 1.4% vs. CSII 7.3 ± 0.9%, p < 0.0001 (0.8% difference pro CSII therapy). Group 1 demonstrated an A1c decrease from 8.7% to 7.3% (1.4% difference). Group 2 mean A1c was 7.1%. Rate of hypoglycemia (< 50 mg/dL) decreased 61% in the ECO and 79% in Group 2. Conclusion: This study reinforces the safety and efficacy of CSII with a robust A1c reduction and hypoglycemia. The pioneer care HSSDF ambulatory attests to be achievable the free dispensing by Unified Health System (UHS) following a protocol, and this approach results in less wastage to the patient and represents a rational policy of therapy with CSII for UHS. Arch Endocrinol Metab. 2015;59(1):23-8

show abstract

“…''Clinicians, day to day, are being forced to make decisions about pump therapy based on a handful of patients,'' said Ian Blumer. The studies from Berthe et al 34 and Wainstein et al 35 found a statistically significant improvement in HbA1c with insulin pump therapy compared with use of MDI. ''The two studies with the largest numbers of patients, although the numbers aren't really large,'' said Blumer, are those published by Raskin et al 36 and Herman et al 37 showing no significant HbA1c difference between pump therapy and MDI in people with T2D.…”

Section: Insulin Pump Therapy In the Management Of Type 1 Diabetes-cumentioning

confidence: 99%

5^thAnnual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 3–5, 2012, Dublin, Ireland

Hoey¹,

Mlinac²,

Tran

et al. 2012

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Effectiveness of Intensive Insulin Therapy by Multiple Daily Injections and Continuous Subcutaneous Infusion: A Comparison Study in Type 2 Diabetes with Conventional Insulin Regimen Failure

Abstract: Pump therapy provides a better metabolic control than injection regimens, and seems to be safe and convenient in patients with type 2 diabetes who fail to respond to conventional insulin therapy.

Cited by 92 publications

References 9 publications

Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes

Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes

Evaluation of diabetic patients after three month use of continuous subcutaneous insulin infusion, dispensed by a protocolled form at outpatient reference clinic of Taguatinga Regional Hospital

5^thAnnual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 3–5, 2012, Dublin, Ireland

Contact Info

Product

Resources

About

Effectiveness of Intensive Insulin Therapy by Multiple Daily Injections and Continuous Subcutaneous Infusion: A Comparison Study in Type 2 Diabetes with Conventional Insulin Regimen Failure

Abstract: Pump therapy provides a better metabolic control than injection regimens, and seems to be safe and convenient in patients with type 2 diabetes who fail to respond to conventional insulin therapy.

Cited by 92 publications

References 9 publications

Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes

Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes

Evaluation of diabetic patients after three month use of continuous subcutaneous insulin infusion, dispensed by a protocolled form at outpatient reference clinic of Taguatinga Regional Hospital

5thAnnual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 3–5, 2012, Dublin, Ireland

Contact Info

Product

Resources

About

5^thAnnual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 3–5, 2012, Dublin, Ireland